Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Efficacy and Safety of Alteplase in Participants With Mild Stroke

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Mild ischemic stroke defined as the most recent pre-treatment NIHSS score of less than or equal to(\</=) 5 and determined as not clearly disabling by the investigator~* Study treatment initiated within 3 hours of last time participant seen normal~Exclusion Criteria:~* Computed tomography (CT) or magnetic resonance imaging (MRI) findings of one of the following:~  1. CT with clear large hypodensity that is greater than (\>) one-third middle cerebral artery (MCA) territory (or \>100 cubic centimeter \[cc\] if not in MCA territory)~ 2. MRI with clear large hyperintensity on concurrent diffusion-weighted (DW) and fluid-attenuated inversion recovery (FLAIR) that is greater than one-third MCA territory (or greater than 100 cc if not in MCA territory),~ 3. Imaging lesion consistent with acute hemorrhage, or~ 4. Evidence of intraparenchymal tumor~* Disability prior to the presenting stroke~* Standard contraindications to IV alteplase within 3 hours of symptom onset, including:~  1. Head trauma, myocardial infarction, or previous stroke within the previous 3 months~ 2. Gastrointestinal or urinary tract hemorrhage within the previous 21 days~ 3. Major surgery within the previous 14 days~ 4. Arterial puncture at non-compressible site within the previous 7 days~ 5. Any history of ICH with the exception of those less than (\<) 5 chronic microbleeds on MRI~ 6. Elevated blood pressure defined by systolic blood pressure \>185 millimeters of mercury (mm Hg) or diastolic blood pressure \>110 mm Hg, or treatments requiring aggressive measures to achieve acceptable levels~ 7. Treatment with unfractioned heparin within past 48 hours and activated partial thromboplastin time outside normal range~ 8. Blood glucose \<50 milligrams per deciliter (mg/dL)~ 9. International normalized ratio \>1.7~ 10. Platelet count \<100,000 per cubic millimeter (/mm\^3)~ 11. Treatment with a direct thrombin inhibitor (dabigatran) or a factor Xa inhibitor (apixaban, rivaroxaban, edoxaban) within the last 48 hours~* Allergic reaction to study drug, aspirin, or nonsteroidal anti-inflammatory drugs (NSAIDs)~* Females of childbearing age who are known to be pregnant and/or lactating~* Inability to swallow, which would prevent oral intake of aspirin or aspirin placebo tablet~* Other serious, advanced, or terminal illness that would confound the clinical outcome at 90 days~* Current or recent (within 3 months) participation in another investigational drug treatment protocol~* Anticipated inability to obtain 3-month follow-up assessments~* Previous enrollment in PRISMS~* Any other condition deemed by the investigator that would pose hazard to the participant with alteplase treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Alteplase Placebo + Aspirin (Type: ACTIVE_COMPARATOR): Participants will receive single dose of IV alteplase placebo and aspirin orally.
- Alteplase + Aspirin Placebo (Type: EXPERIMENTAL): Participants will receive single dose of IV alteplase and aspirin placebo orally.

Based on this trial design, predict the completion outcome and termination type (if applicable).